The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma

Clin Radiol. 2008 Dec;63(12):1297-309. doi: 10.1016/j.crad.2008.05.010. Epub 2008 Aug 21.


Integrated positron-emission tomography/computed tomography (PET/CT) with 2-[fluorine-18] fluoro-2-deoxy-D-glucose (FDG) is now established in the management of oncology patients. With increasing availability and a constantly advancing body of evidence, the role of FDG PET/CT in oesophageal cancer is set to expand to include initial staging, assessment of disease response, therapy planning, and detection of disease recurrence. This article reviews the utility of FDG PET/CT in the management of oesophageal carcinoma, discussing its role and limitations in the imaging of these patients.

Publication types

  • Review

MeSH terms

  • Carcinoma / diagnostic imaging*
  • Carcinoma / pathology
  • Esophageal Neoplasms / diagnostic imaging*
  • Esophageal Neoplasms / pathology
  • Female
  • Fluorodeoxyglucose F18*
  • Humans
  • Male
  • Neoplasm Invasiveness / diagnostic imaging
  • Neoplasm Staging
  • Positron-Emission Tomography / methods*
  • Radiopharmaceuticals*
  • Tomography, Emission-Computed / methods*
  • Whole Body Imaging


  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18